Category Archives: Investment Research

Learn about Investor Shervin Pishevar

Published / by Logan / Leave a Comment

Shervin Pishevar is an angel investor, venture capitalist, published researcher, multiple entrepreneurs, incubation expert, and start-up advisor. Today, Shervin is the Cofounder of two successful ventures, which are Hyperloop Technologies and Sherpa Capital. Sherpa Ventures is a capital firm based in Francisco, and Shervin also works there as the Managing director.

From the love of innovation and technology, Shervin Pishevar has founded several technological- related companies since his early years in the career, explaining his love for technology entrepreneurship. Between 1997 and 2001 Shervin was the CEO of WebOS, which he has founded. He also cofounded Seges Capital and Application Corporation in 2001. From 2001 to 2004, Shervin Pishevar served as the President, Head of Products, Sales, and business development, as well as the Cofounder of Inside Interactive. Shervin also worked with Webs, Inc. as the company’s COO and Founding president between 2005 to 2011.

Shervin Pishevar joined Menlo Ventures in 2011, as the Venture Advisor and managing director. He was really helpful in the Menlo Talent Fund launch, which happened in 2011. The seed fund was worth $20 million. In his position in Menlo, Shervin was able to work closely with teams from Machine Zone, Uber, Warby Parker, Tumblr, and Fab. He had under his management over $4 billion.

Over the years Shervin Pishevar has made a lot of investments to more than 60 companies in different sectors.

Shervin is a member of the Global Entrepreneur Council in the UN Foundation. He is also in the Comscore’s Advisory board. In 2012, Shervin was honored as an “Outstanding American by Choice.” BY Homeland Security Department in 2008. In many state department delegations, Shervin has been appointed Entrepreneurial Ambassador to Russia and the Middle East. In the Obama’s Entrepreneurial Summit in Algeria in 2008, Shervin was the keynote speaker. He also assisted in the creation of the Technology and Innovation plan, by being part of the policy working group. Go Here for related Information.

Shervin Pishevar is an alumnus of University of California, Berkley, where he acquired a bachelors degree in Arts. He is the author of numerous U.S. patents while his research has been published in Neuroscience Letters and JAMA. Since 2015, Shervin has been serving in the board of J. William Fulbright Foreign Scholarship.

Related Article:

How Sahm Adrangi Made Money For His Hedge Fund Betting Against Three Biotech Companies

Published / by Logan / Leave a Comment

Kerrisdale Capital Management LLC is a New York, New York investment management company founded by its chief investment officer, Sahm Adrangi. When he founded this company in 2009 he had been in the financial industry for five years, working as an analyst for three different firms. During this time he had developed extensive experience in financial matters such as leveraged financing, bankruptcy restructuring, and distressed debt.


When Sahm Adrangi started Kerrisdale it had been with money that he had saved coupled with money his parents wanted him to manage as well as other supporters. He started out with $1 million and by July 2017 he had developed this into $150 million in assets under management. He has built up a team of analysts that carry out research that he then uses to make his investment decisions.


Starting in the second half of 2017, Sahm Adrangi started to target businesses in the biotech industry that his research showed were not the great investments that others thought they were. One of these was Bavarian Nordic which was developing a cancer drug. Adrangi had said that their cancer vaccine was a big failure. Once its study on this vaccine was complete it was proven that Sahm had been right. He had shorted this company’s stock which led to a profit windfall for his hedge fund.


Another biotech company that Sahm Adrangi has shorted in last few months is Prothena. Their market cap had exceeded $2 billion on hopes for its AL amyloidosis drug. The analysts working for Kerrisdale said that their research showed this drug had zero promise. Their Phase IIb and Phase III studies on this drug have yet to be completed but he is completely sure that this drug has absolutely no value and expects Prothena’s stock to plummet. Get More Information Here.


Sahm Adrangi had also been proven right about another drug manufacturer in 2017, Sage. He shorted their stock and was proven to have been right to do so not long after. As it turns out the drug that they were developing had turned out to be as ineffective as a placebo.